Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders related to neuronal excitation-inhibition imbalance [1][3] - The company will participate in three upcoming investor conferences, providing opportunities for one-on-one meetings with interested investors [1][4] Company Overview - Praxis utilizes genetic insights from epilepsy to develop therapies for CNS disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - The company has a diversified portfolio that includes multiple programs targeting epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - Praxis will present at the Baird 2025 Global Healthcare Conference on September 9th from 9:00-9:35am EDT [4] - A fireside chat is scheduled for September 10th at the H.C. Wainwright 27th Annual Global Investment Conference at 8:30am EDT [4] - A virtual corporate presentation will take place on September 18th at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit from 3:00-3:30pm EDT [4]

Core Insights - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders through genetic insights [1][2] - The company will have its CEO Marcio Souza participate in a virtual fireside chat hosted by Truist Securities on August 5, 2025 [1] Company Overview - Praxis specializes in translating insights from genetic epilepsies into therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance [2] - The company utilizes its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, to develop therapies for both rare and prevalent neurological disorders [2] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, featuring four clinical-stage product candidates [2]

Core Insights - Praxis Precision Medicines, Inc. is set to report topline results from the RADIANT trial of vormatrigine and its financial results for Q2 2025 on August 4, 2025, before market opening [1] - A live webcast will be hosted on the same day at 8:30am ET, accessible via a registration link and available for replay for 90 days [2] Company Overview - Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for CNS disorders linked to neuronal excitation-inhibition imbalance, utilizing genetic insights [3] - The company employs proprietary platforms, Cerebrum™ for small molecules and Solidus™ for antisense oligonucleotides, to target shared biological mechanisms in the brain [3] - Praxis has a diversified CNS portfolio with multiple programs addressing epilepsy and movement disorders, featuring four clinical-stage product candidates [3]

Company Overview - Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance [3] - The company utilizes genetic insights to create therapies for both rare and prevalent neurological disorders through its proprietary platforms, Cerebrum™ and Solidus™ [3] - Praxis has a diversified CNS portfolio that includes multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates [3] Upcoming Events - The company will participate in three investor conferences, including a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20 at 9:30 am ET [4] - Praxis management will also attend the Mizuho Neuro & Ophthalmology Summit in New York City on May 21 [4] - A corporate overview will be presented at the Jefferies Global Healthcare Conference on June 4 at 8:10 am ET [4] Investor Engagement - The company will be available for one-on-one meetings during all events, encouraging interested investors to contact their representatives [1] - Webcasts of the events will be accessible for 90 days through the "Events & Presentations" page on the company's website [2]